Fig. 1

Reduced pathological phenotype in DC-TNFR2KO mice in the Mannan oligosaccharide (MOS)-induced PsA model. (A). Confirmation of TNFR2 depletion in spleen cells from DC-TNFR2KO (TNFR2^fl/fl / CD11c-Cre) compared to control mice (TNFR2^fl/fl) via FACS analysis. (B) Representative images of ear of TNFR2^fl/fl (control) and DC-TNFR2KO mice treated with vehicle or MOS. (C) Cumulative PASI score (erythema + scaling + thickness) at baseline (day 0) and post MOS injection (day 2, 4 and 6). (D) Representative images of the arthritic phenotype (swelling and redness) and psoriasis-like skin lesions in the hind paws of control and DC-TNFR2KO mice. (E) Mean arthritis severity score of paws and, (F) Grip strength measurements over time. PASI and arthritis severity score were assessed in double blinded manner, with each score representing the mean of three independent scores per mouse (n = 6 per group). Data are presented as mean ± S.E (* p < 0.05; **p < 0.01; *** p < 0.001).